morning welcome scientific second quarter earn call operator instruction today presentation opportunity question operator instruction please note event record would like turn conference vice president investor relation please ahead investor good morning everyone thank join today call chairman chief executive officer executive vice president chief financial officer issue press release earlier morning technical issue result include reconciliation measure release post copy release reconciliation measure today call investor relation section website head financials file duration call approximately hour focus comment performance largely compare technical issue impact future catalyst outlook business include full year guidance review financials quarter provide detail regard full year guidance take question today session join chief medical officer begin like remind everyone call operational revenue growth exclude impact foreign currency fluctuation organic revenue growth exclude acquisition divestiture full period comparable sale relevant acquisition organic growth versus include close march interventional medicine close respectively divestiture include specialty pharmaceutical close march global embolic microspheres portfolio intrauterine health franchise divest second quarter respectively guidance exclude recently announce surgical acquisition expect close second half acquisition expect close subject customary close condition technical issue information please refer slide financial operate highlight deck find investor relation website call reference sale revenue unless otherwise specify organic finally growth goal represent comparison time period result materially impact pandemic note call contain forward look statement within mean federal security identify word like anticipate expect believe estimate similar word include among thing impact pandemic upon company operation financial result statement growth market share product approval launch acquisition clinical trial save growth opportunity cash flow expect financial performance include sale margin earn rate spend expense factor cause difference include describe risk factor section recent subsequent file statement speak today date disclaim intention obligation update point turn comment chairman chief executive thank everyone join today please report strong financial result today resumption elective procedure strengthen improve many certainly region across globe position second half beyond continue execute category leadership strategy drive innovative pipeline expansion faster growth market globalization effort enhance digital capability total company second quarter operational sale grow versus organic sale grow versus versus exceed expectation recovery pandemic occur quickly expect particularly importantly seven business grow double digit organically versus estimate five business unit grow faster respective market please ongoing product launch clinical trial rate adjust grow versus versus exceed high guidance primarily sale outperformance lower spend adjust operate margin slightly ahead expectation continue balance investment sale recovery continue please free cash flow second quarter free cash flow generation million adjust free cash flow million give second quarter outperformance increase narrow guidance range sale assume manageable level impact second half year compare target organic revenue growth full year compare target organic revenue growth full year growth adjust estimate update full year adjust revise range provide detail sale performance outlook include revenue contribution continue expect close second half close surgical provide additional highlight result along comment outlook within region operational basis versus grow middle east grow grow emerge market sale grow organically grow versus strength support faster anticipate recovery procedure volume level along ongoing product launch across entire portfolio operationally deliver excellent broad base growth across nearly major market franchise even country experience relate lockdown procedural delay region also double digit growth endo drive product alpha notable strength middle east north country pacific although result include approximately basis point negative impact tender price versus five business grow double digit strong growth result impact success ongoing product launch ranger sale grow versus strong double digit growth within business unit exception intervention cardiology include negative impact tender price continue please strong growth complex image enable innovative portfolio tender continue expect full year double digit growth versus provide comment business unit start urology pelvic health sale strong grow organically versus balance growth across stone prostate health pelvic health franchise stone largest franchise grow double digit enthusiasm continue ahead acquisition expand category lead urology portfolio differentiate laser technology prostate health franchise grow strong double digit continue strength business growth drive traction direct patient effort unite state global expansion continue appreciation long term durability benefit minimally invasive therapy within business growth support ongoing launch next generation hydrogel recent launch visible need physician important step optimize treatment plan patient undergo prostate radiation therapy endoscopy deliver excellent sale grow organically versus sale grow double digit across major franchise notable strength hemostasis infection prevention thank differentiate product portfolio include product resolution hemostasis clip within quarter complete mark please early launch feedback highlight differentiate visualization suction remain track launch second half continue make progress physician peer train program launch resumption normal market development activity access hospital improve cardiac rhythm management sale organically versus believe performance slightly overall market inclusive temporary impact recent physician advisory importantly recently begin launch enhance electrode anticipate improve performance overall second half expect revenue rebound diagnostics franchise implantable cardiac monitor continue perform gain market share also please strong growth execution continue anticipate full year growth business least forma basis versus electrophysiology sale versus strong international sale growth drive ongoing success force sense catheter sale likely market growth receive approval therapy currently respective trial also exercise option acquire leader pulse field ablation emerge field potential improve safety efficacy ease cardiac ablation procedure company commercially approve pulse ablation product actively advent trial excite bring differentiate therapy portfolio neuromodulation organic revenue grow versus pain management franchise growth accelerate support ongoing launch next alpha system digital solution continue clinical evidence generation year meet release year follow data combo study demonstrate sustain high level clinical functional success responder rate also start report real world result therapy design provide profound immediate pain relief beyond advance outcome exist indication also please progress study focus surgical back population start year look forward begin diabetic peripheral neuropathy study year deep brain stimulation business continue gain share globally deliver strong double digit growth drive launch platform expansion commercial infrastructure partnership interventional cardiology organic sale grow versus double digit growth structural heart valve complex image franchise growth franchise accelerate sequentially impressive growth drive primarily increase hospital physician utilization rate share gain importantly nearly account fully transition exclusively additionally please year result pinnacle feature late breaker reinforce positive year primary outcome meet secondary effectiveness endpoint remain excite outlook franchise next generation device global expansion continue work toward indication expansion ongoing clinical trial notably option trial compare first line oral anticoagulant patient valvular also undergo cardiac ablation procedure recently complete enrollment ahead schedule spite challenge present pandemic launch continue support part real world data present euro demonstrate rate comparable contemporary device continue permanent pacemaker implantation rate outcome reiterate early registry also present last week late breaker cerebral embolic protection device achieve highest quarterly sale date strong account open globally continue enroll protect clinical trial coronary therapy decline single digit versus attributable drug stent include impact tender global price pressure continue strong growth complex image particular strength importantly global complex image business larger business advance opportunity future growth driver within quarter begin enrollment agent trial first study coronary stent restenosis peripheral intervention deliver organic sale versus within interventional oncology grow versus forma basis first full quarter post approval venous continue grow double digit gain share varicose vein market within arterial drug portfolio achieve record sale support global expansion along sector continue recovery please start enrollment registry study gather clinical evidence risk previously underrepresented patient population study also look long term outcome patient treat ranger also like highlight scientific recent inclusion capital list company support healthy family community along recognition best place work disability inclusion proud recognize provide employee inclusive supportive environment remain commit global sustainable practice overall please performance first half year remain bullish long range outlook scientific look forward share strategic plan objective hybrid investor event like extend thank employee contribution spirit turn call executive vice president chief financial second quarter consolidate revenue billion represent report revenue growth versus second quarter reflect million tailwind foreign exchange operational basis revenue growth quarter sale acquisition contribute basis point offset divestiture specialty pharmaceutical result organic revenue growth guidance range growth versus compare second quarter organic growth guidance range growth exclude million sale divest intrauterine health embolic business million sale acquire business consist month full quarter interventional medicine line result drive adjust earn share represent growth versus growth versus exceed guidance range adjust gross margin second quarter slightly expectation drive sale outperformance higher margin business expect materially work drive negative manufacture variance capitalize balance sheet result expect slight improvement second half gross margin compare first half though still full year level headwind remain particular linger plant specific measure impact inflation unique inflation include item like increase freight selective wage pressure price increase direct material second quarter adjust operate margin slightly expectation drive sale outperformance balance investment also include reserve legal settlement expect improve access additional market cardiovascular technology charge within quarter additionally include million litigation relate expense account incremental resolve newly claim know claim correspond legal within legal reserve materially claim remain settle final stage settlement reserve assumption base full global resolution give recent claim activity expect litigation total legal reserve million increase million versus march drive mesh reserve increase cardiovascular settlement partially offset payment close majority state attorney general mesh settlement continue mesh product liability payment move line adjust interest expense total million line expectation rate second quarter adjust basis also line expectation adjust free cash flow quarter million free cash flow million million operate activity million capital expenditure goal remain deliver adjust free cash flow line approximately billion continue expect increase work capital headwind inventory account receivable remainder year cash hand billion priority capital deployment remain tuck continue expect close acquisition surgical second half year capacity pursue additional business development opportunity continue remain active venture capital portfolio consider opportunistic share repurchase billion fully dilute weight average share outstanding walk guidance full year full year expect operational revenue growth range versus include approximate basis point headwind divestiture intrauterine health franchise specialty pharmaceutical partially offset acquisition exclude impact acquisition divestiture expect organic revenue growth range versus versus organic comparison full year sale exclude million sale embolic portfolio intrauterine health franchise million specialty pharmaceutical sale midpoint guidance sale exclude approximately million sale recent acquisition include interventional medicine march million specialty pharmaceutical sale prior divestiture expect operational revenue growth range versus include approximate basis point headwind divestiture specialty pharmaceutical partially offset acquisition exclude impact acquisition divestiture expect organic revenue growth range versus growth versus include basis point sequential comp headwind therefore midpoint guidance assume result line continue manageable level impact organic comparison sale exclude million sale embolic portfolio intrauterine health franchise specialty pharmaceutical midpoint guidance sale exclude approximately million sale acquisition interventional medicine adjust operate margin continue target average back half year simultaneously invest normalize operate expense level first half remain would expect near term rate continue forecast full year operational rate approximately rate approximately continue expect adjust line expense include interest payment dilution venture capital portfolio associate hedge program approximately million million year expect fully dilute weight average share count approximately billion share billion share full year raise full year adjust guidance range include update sale guidance consider result remove additional uncertainty previously wider range third quarter adjust expect range please check investor relation website financial operational highlight outline detail result turn back newly appoint vice president investor relation deserve moderate investor open question next minute order enable take many question possible please limit question relate follow please ahead